Why Estradiol Patch Causes Breast Tenderness: The Mechanism Explained

At a glance

• Label rates / Climara trials: breast pain 5% at 0.025 mg/day, 8% at 0.05 mg/day, 29% at 0.1 mg/day, 4% placebo [1]
• Most common / Breast pain is listed among Climara reactions reported in 10% or more [1]
• Oral label / Breast tenderness, enlargement and pain are listed without frequencies [2]
• Receptor action / Estradiol binds nuclear estrogen receptors; two estrogen receptors vary in proportion by tissue [1]
• Route / The Climara label says systemic availability of estradiol after transdermal use is about 20 times higher than after oral use, with no first-pass metabolism [1]
• Progestogen trial / Oral estradiol valerate plus MPA had the highest breast tenderness prevalence among three groups [3]

What does the Climara patch label report?

The Climara label reports breast pain rates from pooled trials in postmenopausal women, including hot-flush trials and an osteoporosis-prevention trial that contributed to the 0.025 mg/day group: 5% at 0.025 mg/day, 8% at 0.05 mg/day, 29% at 0.1 mg/day and 4% with placebo [1]. Breast pain is also on the label's list of most common adverse reactions, meaning 10% or more in the Climara trials [1]. The same label lists breast pain and breast tenderness among postmarketing reports [1].

Rates rose with patch strength in this table, and the 0.1 mg/day group stood well apart from the others [1]. The label does not explain this pattern.

The oral estradiol tablet label lists breast tenderness, enlargement and pain among adverse reactions without giving frequencies [2]. That label covers oral tablets, not patches.

How is estradiol described as acting?

The Climara label describes estradiol as the principal intracellular human estrogen and says it is substantially more potent at the receptor than estrone and estriol [1]. It says estrogens act by binding nuclear receptors in estrogen-responsive tissues, and that two estrogen receptors have been identified and vary in proportion from tissue to tissue [1]. The label does not connect this receptor action to breast pain.

Does adding a progestogen matter?

A 2018 randomized trial enrolled 96 postmenopausal women; 73 completed it. The trial compared oral estradiol valerate plus medroxyprogesterone acetate, oral estradiol valerate plus micronized progesterone, and Cimicifuga foetida extract. The MPA group had the highest prevalence of breast tenderness, and more than half of all participants reported no symptoms throughout the period [3]. This trial used oral estradiol valerate, not an estradiol patch, so it does not show what happens with a patch plus a progestogen.

Frequently asked questions

›How common is breast pain with the Climara patch?

In Climara trials, breast pain was reported by 5% of women using 0.025 mg/day, 8% using 0.05 mg/day and 29% using 0.1 mg/day, versus 4% with placebo [1]. Breast pain is also listed among the most common Climara reactions, reported in 10% or more of trial participants [1].

›Does the label explain why the patch causes breast pain?

No. The Climara label describes estradiol as acting through nuclear estrogen receptors in estrogen-responsive tissues, but it does not link that action to breast pain [1].

›Does the oral estradiol label also list breast tenderness?

Yes. The oral estradiol tablet label lists breast tenderness, enlargement and pain among adverse reactions and gives no frequencies [2].

›Does a progestogen change breast tenderness with estradiol?

One 2018 randomized trial of 96 postmenopausal women compared two oral estradiol valerate plus progestogen regimens with an herbal extract; 73 women completed it. The group taking medroxyprogesterone acetate had the highest prevalence of breast tenderness [3]. The trial used oral estradiol valerate, not patches.

References

1. U.S. National Library of Medicine, DailyMed. Climara estradiol transdermal system (Bayer) prescribing information. Climara estradiol transdermal system (Bayer) label
2. U.S. National Library of Medicine, DailyMed. Estradiol tablets USP (Teva) prescribing information. Estradiol tablets USP (Teva) label
3. Gao L, Zuo H, Zheng T, Xue W, Wang Y, Deng Y, et al. Influence of hormone therapy or C. foetida extract on breast tenderness in postmenopausal women. Climacteric. 2018. Influence of hormone therapy or C. foetida extract on breast tenderness in postmenopausal women